Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 22;119(5):1146-1160.
doi: 10.1093/cvr/cvac084.

Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state

Affiliations

Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state

Laura A Bosmans et al. Cardiovasc Res. .

Abstract

Aims: CD40 and its ligand, CD40L, play a critical role in driving atherosclerotic plaque development. Disrupted CD40-signalling reduces experimental atherosclerosis and induces a favourable stable plaque phenotype. We recently showed that small molecule-based inhibition of CD40-tumour necrosis factor receptor associated factor-6 interactions attenuates atherosclerosis in hyperlipidaemic mice via macrophage-driven mechanisms. The present study aims to detail the function of myeloid CD40 in atherosclerosis using myeloid-specific CD40-deficient mice.

Method and results: Cd40flox/flox and LysM-cre Cd40flox/flox mice on an Apoe-/- background were generated (CD40wt and CD40mac-/-, respectively). Atherosclerotic lesion size, as well as plaque macrophage content, was reduced in CD40mac-/- compared to CD40wt mice, and their plaques displayed a reduction in necrotic core size. Transcriptomics analysis of the CD40mac-/- atherosclerotic aorta revealed downregulated pathways of immune pathways and inflammatory responses. Loss of CD40 in macrophages changed the representation of aortic macrophage subsets. Mass cytometry analysis revealed a higher content of a subset of alternative or resident-like CD206+CD209b- macrophages in the atherosclerotic aorta of CD40mac-/- compared to CD40wt mice. RNA-sequencing of bone marrow-derived macrophages of CD40mac-/- mice demonstrated upregulation of genes associated with alternatively activated macrophages (including Folr2, Thbs1, Sdc1, and Tns1).

Conclusions: We here show that absence of CD40 signalling in myeloid cells reduces atherosclerosis and limits systemic inflammation by preventing a shift in macrophage polarization towards pro-inflammatory states. Our study confirms the merit of macrophage-targeted inhibition of CD40 as a valuable therapeutic strategy to combat atherosclerosis.

Keywords: Atherosclerosis; CD40; Inflammation; Macrophage.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: C.W., D.A., E.L. and N.G. are supported by the Deutsche Forschungs Gemeinschaft (grants CRC1123, A5, SFB 1123, TRR259, SFB1116). E.L is also supported by the Netherlands CardioVascular Research Initiative, the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences’ for the GENIUS project ‘Generating the best evidence-based pharmaceutical targets for atherosclerosis’ (CVON2011-19), and the ERC Con grant (CD40-INN). E.L. is also the vice chair at the ESC working group on atherosclerosis, serves on the EAS programme committee and the ATVB awards and programme committee and has received payment or honoraria for lectures at Novartis and Novo Nordisk. The remaining authors have nothing to disclose.

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
CD40 deficiency and inflammation in CD40mac−/− mice. CD40 expression in LPS or control stimulated BMDMs isolated from CD40mac−/− compared to CD40wt mice (A; n = 3 mice; pooled cells, n = 6 technical replicates). Western blot showing CD40-expression after stimulation with LPS in CD40wt and CD40mac−/− BMDMs (B; n = 3 mice, pooled cells, representative blot shown with an α-tubulin loading control ∼50 kDa.). Flow cytometric analysis of 22 weeks old CD40wt and CD40mac−/− showing ratios of circulating CD45+CD11b+Ly6G- monocytes, CD45+CD11b+Ly6G+SiglecF+ neutrophils, CD45+CD11b+Ly6G-SiglecF+ eosinophils, CD45+CD11b+CD11c+MHCII+ dendritic cells in (C), ratios of circulating CD45+CD19+ B-cells and CD45 + CD3+ T-cells in (D) and ratios of CD45 + CD3 + CD4/8 + CD62L+/-CD44-/+ effector, naïve and memory T-cells in CD40wt and CD40mac−/− lymph nodes (E). Gene expression in CD40wt and CD40mac−/− lymph nodes of chemokines and cytokines analysed by qPCR (mRNA gene expression presented as fold-change against the respective housekeeping gene) is shown in (F), and by Luminex of plasma in (G). N = 8/6 for CD40wt and CD40mac−/− mice, respectively, in C; n = 7 in (DE); n = 10/12 mice, respectively, in (F), and n = 14/18 mice, respectively, in (G). Data is shown as mean ± SD. Statistical analyses were performed using the unpaired t-test in (AB) and the Mann–Whitney U test (with multiple comparisons adjusted for using the Holm-Šídák test) in (CG).
Figure 2
Figure 2
Reduced atherosclerosis in the aortic arch of CD40mac−/− mice. Lesion size (A) and mac3+ macrophage content (B) in CD40wt and CD40mac−/− aortic arches. Mac3+ macrophages (C) and CD206+ cell (D) content was further quantified separately in initial and advanced plaques. Necrotic regions were quantified in CD40wt and CD40mac−/− aortic arches (E; representative haematoxylin & eosin stain with necrotic areas marked by dashed lines). In vitro collagen production by primary murine VSMCs isolated from CD40-deficient and wild-type mice (F) and in immortalized murine VSMCs after stimulation with conditioned media from naïve, LPS- or IL4-activated primary CD40wt and CD40mac−/− BMDMs (G). Flow cytometric analysis of efferocytosis in primary bone marrow-derived macrophages isolated from CD40wt and CD40mac−/− mice (H). N = 19/17 mice, respectively, in (A), n = 17 mice in (B), n = 110 CD40wt/142 CD40mac−/− plaques, from n = 17 mice in (C), n = 90 CD40wt/102 CD40mac−/− plaques from n = 16/19 mice, respectively, in (D), n = 16/17 mice, respectively, in (E), n = 4 replicates in (F), n = 3 replicates in (G), and n = 6 replicates in (H). Scale bars represent 500 µm in (A) and 200 µm in (B) and (E). Data is shown as mean ± SD. Statistical tests were performed using the Mann-Whitney U test in (A–E) and the unpaired student’s t test in (FH).
Figure 3
Figure 3
CD45+ cell populations in the atherosclerotic aorta of CD40wt and CD40mac−/− mice assessed by CyTOF analysis. Seven CD45+ leukocyte populations were identified by viSNE analysis: CD11b+ myeloid cells, Ly6G/C+ neutrophils, SiglecF+ eosinophils, CD103+ type 1 conventional dendritic cells (cDC1s), CD19+ B-cells, CD90.2+ T-cells and CD161+ natural killer (NK) cells (A; composite of all cells measured), with cell composition in CD40mac−/− compared to CD40wt mice shown in (B). N = 12/13, respectively for CD40wt and CD40mac−/− mice, with each sample representing two pooled aortas resulting in a final n = 6 samples. Statistical analyses were performed using a multiple t-test with P-values adjusted according to discoveries determined using the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli (Q = 1%).
Figure 4
Figure 4
Increased M2 macrophage ratio in CD40-deficient atherosclerotic aortas. Within the CD45+CD11b+ myeloid cell population in the atherosclerotic aorta eight sub-populations were identified (after neutrophil and eosin populations were subtracted): CD206+CD209b and CD206+CD209b+ macrophages, CCR2+ macrophages, CD11c+ macrophages, CD26- and CD26+ type 2 conventional dendritic cells (cDC2) and Ly6C and Ly6C+ monocytes (A; composite of all cells measured) with cell composition in CD40mac−/− compared to CD40wt mice shown in (B). N = 12/13, respectively, for CD40wt and CD40mac−/− mice, with each sample representing two pooled aortas resulting in a final n = 6 samples. Statistical analyses were performed using a multiple t-test with P-values adjusted according to discoveries determined using the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli (Q = 1%).
Figure 5
Figure 5
Macrophage genes and pathways affected by CD40-depletion identified by RNA-sequencing. Volcano plot showing CD40wt versus CD40mac−/− BMDMs (stimulated with FGK45 and IFNγ (A). Top affected functions in CD40mac−/− BMDMs were identified by IPA (B). Levels of IFNγ, IL-17A, IL-18, CXCL2 and CXCL10 were decreased in CD40mac−/− compared to CD40wt BMDMs (following a stimulation pulse by lipopolysaccharide/IFNγ) as analysed by Luminex (C). Black dashed lines represent cut-off values (adjusted P-value = 0.05, Log2 fold change = 1). Red dashed lines represent an adjusted P-value = 0.05. N = 3 technical replicates of cells isolated from n = 3 mice. Statistical tests were performed using the Mann–Whitney U test in (C), with data shown as mean ± SD.
Figure 6
Figure 6
Gene expression resulting from CD40-triggering in native and oxLDL-loaded BMDMs. Gene expression levels relating to classical and alternative macrophage activation are shown in (A), and the main up-regulated pathways identified by IPA pathways analysis are shown in (B). N = 3 technical replicates. Grey boxes represent genes with non-significant z-scores or genes lacking sufficient information to produce z-scores.
Figure 7
Figure 7
Genes and pathways of the aorta affected by myeloid-specific CD40-depletion identified by RNA-sequencing. Volcano plot showing CD40mac−/− versus CD40wt aortas (A). Differentially regulated pathways in CD40mac−/− and CD40wt aortas were identified by GSEA (B). The top 25 main upstream activated/inhibited regulators were identified by IPA pathways analysis (C; red boxes represent –Log10P-values and grey boxes represent activation z-scores). Black dashed lines represent cut-off values (P-value = 0.05, Log2 fold change = 1). Red dashed lines represent an adjusted P-value = 0.05 and green dashed lines represent an unadjusted P-value = 0.05. N = 5 mice.

Similar articles

Cited by

References

    1. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgozoglu L, Lewis EF. Atherosclerosis. Nat Rev Dis Primers 2019;5:56. - PubMed
    1. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ, Investigators C. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752–762. - PMC - PubMed
    1. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group . Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–1131. - PubMed
    1. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L’Allier PL, Guertin MC, Roubille F. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381:2497–2505. - PubMed
    1. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404–410. - PubMed

Publication types